Fox Run Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Fox Run Management’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-25,170	Closed	-$587K	–	948
2025 Q4	$587K	Buy	25,170 +12,052	+92%	+$268K	0.09%	424
2025 Q3	$258K	Buy	+13,118	New	+$270K	0.04%	737
2025 Q2	–	Sell	-57,118	Closed	-$1.39M	–	931
2025 Q1	$1.39M	Buy	57,118 +19,136	+50%	+$431K	0.21%	97
2024 Q4	$793K	Sell	37,982 -7,668	-17%	-$165K	0.14%	247
2024 Q3	$908K	Buy	+45,650	New	+$846K	0.2%	161
2024 Q2	–	Sell	-27,853	Closed	-$444K	–	826
2024 Q1	$444K	Buy	+27,853	New	+$420K	0.1%	412
2023 Q4	–	Sell	-33,877	Closed	-$396K	–	767
2023 Q3	$396K	Buy	+33,877	New	+$453K	0.12%	346

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Fox Run Management's CPRX Position: Q1 2026 in Review

Fox Run Management sold out of Catalyst Pharmaceutical (CPRX) in Q1 2026, closing a stake of 25,170 shares — an estimated $587K sold.

Fox Run Management first reported a position in CPRX in Q3 2023 and held it in 7 quarters. The position peaked at $1.39M in Q1 2025. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

Fox Run Management reported no remaining Catalyst Pharmaceutical position as of Q1 2026 after selling out during the quarter.
Fox Run Management sold 25,170 Catalyst Pharmaceutical shares in Q1 2026, an estimated $587K.
Fox Run Management first reported a position in Catalyst Pharmaceutical in Q3 2023 and held it in 7 quarters.
Fox Run Management's Catalyst Pharmaceutical position peaked at $1.39M in Q1 2025.
380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Fox Run Management's 13F filing for Q1 2026, filed 12 May 2026.